Ipamorelin: Selective Growth Hormone Secretagogue Research Overview

Ipamorelin was designed in the late 1990s by Raun and colleagues as part of an effort to develop selective growth hormone secretagogues for preclinical research. The compound was specifically engineered to retain activity at the ghrelin receptor (GHS-R1a) while minimizing the cross-reactivity with cortisol- and prolactin-releasing pathways that characterized earlier secretagogues.^[1]

The ghrelin receptor (GHS-R1a) is distinct from the GHRH receptor. While GHRH agonists (Tesamorelin, Sermorelin, CJC-1295) target the GHRHR on pituitary somatotrophs, ghrelin/secretagogue agonists like Ipamorelin target a separate receptor that converges on similar growth hormone release pathways downstream. Ipamorelin is therefore studied in the context of receptor-system synergy between GHRH and ghrelin signaling.^[2]

Ipamorelin is studied as a research reference compound in controlled laboratory settings. It has not been approved by the FDA for any human therapeutic, diagnostic, or medical purpose.

Ipamorelin's structural features:

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 residues, with non-natural amino acids)

• Molecular formula: C₃₈H₄₉N₉O₅

• Molecular weight: approximately 711.86 Da

• C-terminal amidation: present (the -NH₂ terminus)

• Non-natural residues: Aib (alpha-aminoisobutyric acid), D-2-Nal (D-2-naphthylalanine), D-Phe (D-phenylalanine)

The use of non-natural and D-configured amino acids in Ipamorelin's design contributes to enzymatic stability and to the selectivity profile distinguishing it from natural ghrelin. Aib at the N-terminus is a common synthetic peptide modification used to constrain conformation and resist degradation. D-amino acids alter substrate specificity for endogenous peptidases.^[1]

The C-terminal amide (rather than free carboxylate) is similarly common in synthetic peptide design, providing modest enzymatic protection at the C-terminus.

Ipamorelin's receptor profile has been characterized through cell-based binding and signaling assays.

Ipamorelin binds to GHS-R1a as a full agonist and activates downstream Gq-coupled signaling, leading to inositol phosphate accumulation and calcium mobilization in cells expressing the receptor. The compound's affinity and efficacy at this receptor are similar to those of natural ghrelin in preclinical assays.^[3]

Unlike some earlier growth hormone secretagogues, Ipamorelin shows minimal cross-activity at ACTH-releasing or prolactin-releasing pathways in preclinical pituitary preparations. This selectivity has been a defining feature of the compound in the research literature.^[1][4]

Because GHRH and ghrelin receptor systems converge on GH release, combination studies pair Ipamorelin with GHRH analogs (Sermorelin, CJC-1295, Tesamorelin) in preclinical pituitary models to examine signaling synergy. The two receptor pathways are not redundant, they contribute independently to pulsatile GH secretion patterns.^[2][5]

Ipamorelin literature spans several research domains.

Animal models with serial blood sampling to characterize GH pulse amplitude and frequency are standard substrates for ghrelin-receptor agonist research. Ipamorelin is frequently included as a comparator or test compound in these studies.^[5]

The Ipamorelin + CJC-1295 (without DAC) combination is among the most studied preclinical pairings in growth hormone secretagogue research. The combination targets both the GHRHR and GHS-R1a receptor systems simultaneously.^[2]

Animal models examining bone density and connective tissue have included Ipamorelin in preclinical experimental arms, leveraging the compound's GH axis stimulation for endpoints in growth hormone-responsive tissues.^[6]

Ipamorelin's design (Aib, D-amino acids, amidated C-terminus) gives it relatively favorable stability compared to native ghrelin. Storage and reconstitution follow standard practices.

Lyophilized Ipamorelin is stored at minus 20 degrees Celsius for long-term preservation. Brief refrigerated storage at 4 degrees Celsius is acceptable for actively used material. Reconstituted solution is used within 4 to 6 weeks at 4 degrees Celsius.

Bacteriostatic water or sterile water are standard reconstitution solvents for laboratory preparations.

Quality is verified by HPLC for purity (greater than or equal to 99 percent), mass spectrometry for identity confirmation matching the modified pentapeptide structure, and endotoxin testing. Each batch of Instant Peptides Ipamorelin ships with a full Certificate of Analysis.

Instant Peptides supplies Ipamorelin as a synthetic lyophilized reference compound in 10mg vials. Material is supplied to qualified research professionals and scientific institutions. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.